Author | Jedd D. Wolchok, MD, PhD | OncLive

Author | Jedd D. Wolchok, MD, PhD

Articles

Dr. Wolchok on Weighing Risk and Benefit of Nivolumab/Ipilimumab Combo in Melanoma

April 05, 2017

Video

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses weighing the overall survival (OS) benefit with the increased risk of toxicities seen with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in treatment-naïve patients with advanced melanoma.

Dr. Wolchok on Progress After Anti-PD-1 Monotherapy in Melanoma

December 29, 2016

Video

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Department of Medicine and Ludwig Center at Memorial Sloan Kettering Cancer Center, 2014 Giant of Cancer Care in Melanoma, discusses an ongoing clinical trial that will explore optimal treatments for patients with melanoma who fail on a PD-1 inhibitor as a single agent.

Dr. Wolchok on the Safety Profile in CheckMate-067 in Melanoma

September 15, 2016

Video

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Department of Medicine and Ludwig Center at Memorial Sloan Kettering Cancer Center, discusses the safety profile in the CheckMate-067 trial, which examined nivolumab combined with ipilimumab in treatment-naïve patients with advanced melanoma.

Dr. Wolchok on Updated CheckMate-067 Results for Melanoma

June 22, 2016

Video

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Department of Medicine and Ludwig Center at Memorial Sloan Kettering Cancer Center, discusses the updated findings from the CheckMate-067 trial, which explored nivolumab (Opdivo) combined with ipilimumab (Yervoy) in treatment-naive patients with advanced melanoma.

x